How to Evaluate a Biotech Startup at Series B: Investor Framework
Biotech offers potential for transformative returns: a single FDA approval can generate billions in revenue. Strong IP protection creates durable moats. Partnership and acquisition exits at clinical stages provide M&A liquidity. This guide covers a 7-step evaluation framework specifically designed for Biotech startups at the Series B stage.
7-Step Evaluation Framework: Biotech at Series B
Verify the Founding Team
For Biotech startups, the team is the primary investment signal at early stage. Check: (1) domain expertise in Biotech — does the team have direct experience in the industry they're disrupting? (2) prior startup experience and exits; (3) LinkedIn verification of claimed roles and credentials; (4) GitHub activity for technical founders; (5) reference calls with former colleagues or investors.
Validate Traction Metrics
The most important metric for Biotech at this stage is Clinical Stage. Benchmark: IND Filed → Phase I → Phase II → Phase III → FDA Submission. Each stage transition is a major de-risking milestone. Always request underlying data — bank statements, CRM exports, or platform data — rather than trusting deck figures alone.
Screen for Sector-Specific Red Flags
Biotech pitch decks frequently contain these critical red flags that general DD frameworks miss: No composition-of-matter patent — only method patents (CRITICAL): Method patents are weak protection. Composition-of-matter patents protect the molecule/therapy itself and are the foundation of biotech IP strategy.. Animal efficacy data in non-validated disease models (HIGH): Many animal models don't predict human outcomes. Investors have been burned by companies with strong rodent data that failed in humans.. Lead scientist departing or not committed full-time (CRITICAL): Biotech founding is inseparable from the scientific founder. Key scientist departure is catastrophic for clinical credibility and pipeline.
Validate Market Size Independently
The Biotech market is $700B+ (global biopharmaceutical market), growing at 8% CAGR through 2030. Validate TAM sourcing: is it bottom-up or top-down? Does the SAM represent the realistic addressable segment within the company's go-to-market reach? Cross-reference with industry reports and comparable company data.
Map the Competitive Landscape
Biotech investors have seen multiple generations of competition in this category. Key comparables: Moderna (IPO 2018 → $200B+ peak market cap), Agenus (acquired) (Multiple pharma partnerships). Ask explicitly about differentiation from each — vague answers signal incomplete competitive awareness.
Conduct Regulatory & Compliance Review
Biotech startups face specific regulatory risks: FDA IND/NDA/BLA pathway: multiple review cycles, advisory committee meetings; Clinical trial regulations: GCP compliance, IRB approval, informed consent; Drug pricing scrutiny: IRA Medicare price negotiation for high-cost drugs; EU EMA: separate approval pathway for European markets. Verify compliance posture before advancing to term sheet.
Synthesize and Assign Investment Verdict
Combine all findings into a structured verdict: INVEST (clear thesis, strong team, de-risked execution), DIG DEEPER (promising but unresolved questions), or PASS (fundamental flaws in team, market, or traction). DDR automates this synthesis and assigns a score from 1–10.
What Series B Investors Specifically Look For in Biotech
- $3M–$15M ARR with >100% YoY growth
- Proven sales motion: full quota-carrying team with attainment data
- Expansion into new segments or geographies underway
- Net Revenue Retention consistently above 110%
- Gross margin expansion visible in historical data
- Clear path to profitability or capital efficiency
Series B Red Flags (Stage-Specific)
- ARR growth decelerating below 80% YoY
- Sales team hiring not keeping pace with pipeline
- NRR declining (early product-market fit decay)
- Key executive attrition in past 12 months
- Customer concentration still above 30% in top 3
Biotech Due Diligence — All Guides
Screen Any Biotech Startup in 5 Minutes
Upload a pitch deck PDF and DDR automatically runs this full due diligence framework — 13 OSINT sources, founder verification, all sector-specific red flags, comparable company analysis, and INVEST/PASS verdict.
GET YOUR FREE SCAN →